Dormant Breast Cancer Cells Hide Behind Cellular Shields, New Study Shows

When scientists first peered into breast tumours with ultra‑high‑resolution tools, they expected to see a chaotic jumble of rapidly dividing cancer cells. What they actually found was something far more nuanced – distinct islands where the cancer seemed to be taking a nap.

In a collaboration between the Medical Research Council Laboratory of Medical Sciences, Imperial College London and UCL’s Genetics Institute, researchers built a cell‑by‑cell atlas of breast tumours and uncovered quiet, “quiescent” cancer cells tucked away behind what looks like a protective cellular shield.

These dormant cells aren’t just idle bystanders. Like bears that hibernate through harsh winters, they can survive the onslaught of chemotherapy, lying low until the environment becomes more hospitable – a situation that may explain why many patients experience a painful relapse months or years after seemingly successful treatment.

"Quiescent cancer cells are very dangerous," says Dr. Alexis Barr, co‑lead author and head of the Cell Cycle Control group at the MRC Laboratory. "They hide from chemotherapy, linger in a dormant state, and later spring back to drive tumour growth again."

The team started by mining publicly available single‑cell RNA‑sequencing data, then layered that information onto spatial transcriptomics maps that pinpoint exactly where each cell sits within the tumour. The result? A vivid picture of two contrasting neighbourhoods – one bustling with fast‑growing tumour cells, the other a quiet suburb populated by dormant cells.

What’s striking is who lives next door to those sleeping cells. The researchers repeatedly spotted CXCL10‑positive macrophages – a type of immune cell – and myofibroblastic cancer‑associated fibroblues (CAFs) forming a tight ring around the quiescent cancer cells. It’s as if the tumour builds a little fortress, shielding its most elusive residents from the body’s defences and from drugs that target dividing cells.

"The cancer cells are really encapsulated within these areas of macrophages and fibroblasts that we think act as shields," explains Dr. Maria Secrier, who led the computational analysis at UCL. "Whether the shield forces the cells into dormancy or the dormant cells recruit the shield is still up for debate – probably a bit of both."

Why does this matter? Most chemotherapy agents are designed to attack cells that are busy copying their DNA. Dormant cells, being idle, simply slip under the radar. The new findings suggest that a one‑size‑fits‑all approach to cancer treatment may be insufficient. Instead, doctors might need a toolbox that includes drugs targeting the protective niche itself – perhaps by disrupting the complement pathway that was found to be especially active in those quiet corners, or by modulating the behaviour of the surrounding macrophages and fibroblasts.

Another surprising twist was that these quiescent pockets appeared not only in slow‑growing tumour subtypes, but also in aggressive forms of breast cancer. That challenges the old notion that dormancy is a hallmark of less aggressive disease.

Going forward, the researchers hope to translate these insights into therapies that can either awaken the sleeping cells – making them vulnerable to standard chemotherapy – or dismantle the shield so that the immune system can recognize and eliminate them.

"If we want long‑term control of tumours and to prevent relapse, we have to focus on these dormant cells and the neighbourhood they live in," says Dr. Barr. "It’s a whole new frontier in breast‑cancer biology, and one that could change how we think about treatment after surgery or chemo."